Long‐acting beta2‐agonists vs placebo
FEV1 · patients with chronic obstructive pulmonary disease
Long‐acting beta2‐agonists showed no clear difference in predose FEV1 (mL) compared with placebo (low certainty).
1 finding from 1 review
- Long‐acting beta₂‐agonists for chronic obstructive pulmonary disease 2013 · Cochrane Headline outcomes onlyMD 7314 studies · 6125 participantsLow